Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared a post on X:
“Pluvicto FDA approval pre-chemo based on PSMAfore in prostate cancer.
Lu-PSMA-617 versus ARPI switch in taxane-naïve mCRPC patients:
- Delayed worsening in pain + HRQoL + less AEs
- rPFS met
- no OS difference but results are likely confounded by rate of crossover.”
